1. SUB-TYPE OF MDS:Patients newly diagnosed with CD123 positive adverse genetic risk acute myeloid leukaemia (AML), including patients with CD123 positive AML secondary to MDS
2. SEVERITY OF MDS: AML
3. NAME OF DRUG: UCART targeting CD123 positive leukaemia cells
4. Aims and benefits: This is a phase 1 first in human study to determine the safety and effectiveness of multiple infusions of UCART123 (specially engineered T-cells that target leukaemia cells that express CD123).

1. Basic inclusion criteria:
   • Aged 18 - 65 years
   • Weight ≥42 kg
   • Patients must have received 1 of the 2 trial-stipulated induction chemotherapy regimens
   • Availability of a suitable sibling or unrelated HLA matched donor
   • ECOG performance status of 0 or 1
2. Basic exclusion criteria:
   • Patients with ≥ 20% blasts in bone marrow after 1 or 2 courses of standard intensive induction chemotherapy
   • Patients with AML transformed from previously diagnosed myeloproliferative disorder
   • Patients with APL
   • Evidence of CNS leukaemia on CSF examination
   • AML relapsing after first complete remission
   • Prior allogeneic stem cell transplant
   • Therapy-related AML
   • Favourable or intermediate risk AML
   • Prior gene or experimental cellular therapy
   • HIV/HBV/HCV Infection
3. Trial sites/locations and name of physician in charge of trial (none are currently recruiting):
   • Kings College Hospital

Please read information and always discuss trial information with your own physician.